Skip to content

The Impact of Telemonitoring in the Management of Hypertension

HOme telemonitoRing of Arterial hypertensiOn With antihypertenSive Treatment Titration: a Randomized COntrolled prosPEctive Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04607239
Acronym
HOROSCOPE
Enrollment
460
Registered
2020-10-29
Start date
2020-07-04
Completion date
2021-07-30
Last updated
2020-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Services Administration, Hypertension, Telemedicine

Keywords

Telecommunication, Telecare, Teleconsult, Telemanagement, Telemonitoring

Brief summary

Rater blinded, multi-center, prospective, randomized controlled study comparing mean 24 hour systolic blood pressure of eligible hypertensive patients in the TELEMONITORIN group versus the USUAL CARE group, at 6 months after inclusion.

Interventions

PROCEDURETelemonitoring

* A weekly telephone call by the CRA for the collection of home blood pressure measurements (which the patient measures twice a day everyday), for therapeutic education, and for treatment compliance assessment. * A monthly call by the attending physician for treatment titration and side effects check.

PROCEDUREUsual Care without Telemonitoring

* Attending the follow up visits after inclusion at Day 90 (D-90) & Day 180 (D-180) for face to face consultation with the attending physician. * Usual care without any phone calls for therapeutic education, treatment compliance assessment, treatment titration or side effects check.

Sponsors

Les Laboratoires des Médicaments Stériles
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Intervention model description

The interventional group (Telemonitoring) in addition to the usual care group (conventional) will benefit from: * a weekly telephone call for collection of home Blood Pressure measurements , therapeutic education & treatment compliance check * a monthly call for treatment titration and side effects check

Eligibility

Sex/Gender
ALL
Age
35 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Included are patients with: * age ≥ 35 years old * newly diagnosed hypertention * uncontrolled hypertention

Exclusion criteria

Excluded are patients with: * orthostatic hypotension * chronic renal failure (serum creatinine \> 200 micromol / L) * acute coronary syndrome * coronary revascularization or stroke within the past 3 months * known secondary causes of hypertension * pregnancy * New York Heart Association Class III or IV heart failure or left ventricular ejection fraction \< 30% * dementia or another cause that prevents the application of remote monitoring

Design outcomes

Primary

MeasureTime frameDescription
Mean of 24h systolic blood pressure (SBP)0 - 180 daysThe change from baseline of mean 24-hour systolic blood pressure (SBP) at 6 months of follow-up

Secondary

MeasureTime frameDescription
Mean of 24h diastolic blood pressure (DBP)0-180 daysThe change from baseline of mean 24 hour diastolic blood pressure (DBP) at 6 months of follow-up
percentage of blood pressure load0-180 daysThe change of blood pressure load's percentages between baseline and 6 months of follow-up
percentage of Dipping0-180 daysThe change of dipping percentages between baseline and 6 months of follow-up
Mean of the Short Form survey (SF-12) scores0-180 daysThe change in the mean of SF-12 scores between baseline and 6 months of follow-up
frequency of cardiovascular complications180 daysClinical outcomes including hospitalization rate, emergency room admissions related to high blood pressure, adverse effects, or other reasons

Countries

Tunisia

Contacts

Primary ContactSemir NOUIRA, Prof
semir.nouira@rns.tn0021673106085
Backup ContactSonia BEN HAFAIEDH, MD
s.hafaiedh@medis.com.tn0021698709311

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026